← All trials
NCT04385420
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 24, 2019
- Primary completion
- Aug 26, 2019
- Completion date
- Aug 26, 2019
- First posted
- May 12, 2020
- Last posted
- May 13, 2020
- Enrollment
- 70
- Arms / groups
- 9 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Atriva Therapeutics GmbHLead sponsor
- SGS Life SciencesCollaborator
- SGS Life SciencesOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.